What is SDGR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.73B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SDGR?

P/E (TTM) is n/a and 52-week range is $10.95 to $33.78 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SDGR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SDGR?

The company profile lists revenue (TTM) near $255M, net income (TTM) near -$5.36B, EPS (TTM) near -$0.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Schrodinger Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 74.7M shares outstanding, ISIN US80810D1037 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Schrodinger Inc

$SDGR

Health Care · Health Care Technology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 850 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

Employees

850

Website

www.schrodinger.com

IPO

2020-02-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)